• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

An MD and DVM Q&A with Dr. Opal

March 1, 2010
Steven Opal, MD

Dr. Steven Opal answers your questions about the flu and kids, cats, and more

Q. What about cats and H1N1?

A. The outbreak in Minnesota on pig farms was probably an example of human-to-animal transmission of the virus. So pigs can get the virus from people. Although this virus can exist in other species, although it remains most prevalent in avian as opposed to mammalian species.

Q. Since trans-species transmission occurs and sick kids stay home with their pets, should we be concerned?

A. Cats and other pets can occasionally become infected with human influenza viruses. I am not sure about the degree to which that is important in the epidemiology of continuing either the human or animal disease. Depending on the virus and on the season, influenza can cause significant respiratory illness in pigs, and in certain years, it can have significant impact on the pig population. Birds usually tolerate influenza well; they get a diarrheal illness but it is usually not fatal.

Advertisement

Q. In the event of a mutation that involves the H5 portion of the avian flu, is it likely that the current H1N1 vaccine will offer some immunity to those who have been vaccinated, or is it completely unpredictable?

A. The major immunodominant epitope of influenza is hemagglutinin. So if it is H5, it is a totally separate immune response from H1N1. Should a need arise, there is a huge stockpile of H5 vaccine, but we would probably have to get another immunization. The thing that makes us concerned is that the H5 has a fairly high mutation rate—the virus is changing in the bird population. It is possible that the vaccine we stockpiled against avian H5N1 a few years ago will not be all that effective should the avian virus begin circulating with human-to-human transmission in 2010. The stockpiled vaccine might not give optimal protection if the avian H5N1 virus keeps mutating over time.

Q. Although ventilators and better treatments are now available, could our healthcare system still become overwhelmed should a 1918-like situation arise?

A. No vaccine for H1N1 was available through the whole flu season in the Southern Hemisphere. The capabilities of critical care specialists, emergency rooms, and ventilators were stretched but not overwhelmed. Based on their experience and because of the relative avirulence of new H1N1, should the same thing happen in the Northern Hemisphere, I expect that we would be able to weather the storm.

Q. A lot of kids have been presumably exposed to influenza—their flu was not typed at the time of their illness, but they are assumed to have had H1N1. Should these children be vaccinated against H1N1?

A. People in the Northern Hemisphere who had the flu in the summer or fall of 2009 most assuredly had new H1N1 and are probably protected from becoming infected again. Is there a risk of immunizing these kids? No. People who have the antibodies tolerate the vaccine as well as people who do not have the antibodies.1 Although there is not huge experience with this vaccine, there is no evidence that suggests that previous exposure would cause more vaccine reactions.

Q. What are the prospects of seeing a more modern manufacturing process than egg passage?

A. A tissue culture system has been developed, but eggs are still a good way of increasing the viral titers. But the tissue culture system now works to increase the viral titers as quickly as occurs in allantoid membrane, so it will likely become the standard of care within the next two years. It will be great when that happens because it is much easier to upscale tissue culture system production than egg-based systems. That improved technology is coming, but, unfortunately, it was not available in 2009.

REFERENCE

1. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-48.

Related Content:

Infectious Diseases
Breakthrough approach for treating mastitis in dairy cows
Breakthrough approach for treating mastitis in dairy cows
Protecting dogs against seasonal infection
Protecting dogs against seasonal infection
Unusual parasite strain kills 4 California sea otters
Unusual parasite strain kills 4 California sea otters

Advertisement

Latest News

Pride, representation, and inclusion in vet med

Partnership to promote diversity in veterinary medicine and more

Morris Animal Foundation accepting canine cancer research proposals

AI-enhanced MyLabX90VET ultrasound system unveiled

View More Latest News
Advertisement